stars 1 stars 2 stars 3

Functional Neuromodulation Ltd. is investigating the use of deep brain stimulation of the fornix (DBS-f) to drive neural activity and modulate the brain’s memory circuit. The company completed a Phase II multi-center clinical trial of DBS-f in 42 patients with mild probable Alzheimer’s. Functional Neuromodulation is dedicated to advancing the application of deep brain stimulation (DBS) therapies to help improve the lives of people with mild Alzheimer’s disease. CAUTION — Investigational device. Limited by Federal law to investigational use

Functional Neuromodulation Questions

Lisa Fosdick is the Vice President Global Clinical Operations of Functional Neuromodulation.

3 people are employed at Functional Neuromodulation.

Top Functional Neuromodulation Employees

G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users